GIBSON DUNN

Gibson Dunn Advises Merck on $10 Billion Verona Pharma Acquisition

Firm News | July 9, 2025

Gibson Dunn is advising Merck & Co., Inc., one of the world's largest pharmaceutical companies, on its $10 billion acquisition of Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases. The Gibson Dunn antitrust team includes partners Steve Weissman and Michael Perry and associate Tristan Locke.

Related People

Stephen Weissman

Michael J. Perry

Related Capabilities

Antitrust and Competition

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**